Compare iShares MBS ETF (MBB) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MBS ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? iShares MBS ETF trades at $89.75 (market cap $35.41B), while Vertex Pharmaceuticals Incorporated trades at $509.5 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 3.6× iShares MBS ETF's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, iShares MBS ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MBS ETF for 96 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| MBB | VRTX | |
|---|---|---|
Market Cap | $35.41B | $127.55B |
Volume | 5,388,525 | 1,487,944 |
Sector | Fixed Income | Health |
52-Week High | $96.91 | $557.96 |
52-Week Low | $89.09 | $407.37 |
Typical Hold Time | 96 Days | 120 Days |
Enterprise Value | — | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MBB, the iShares MBS ETF, trades at $89.68, up 0.52% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock recently hit a new 52-week low of $91.02 on September 15, 2026, as short interest surged 98.3% in September, reflecting negative sentiment. Recent news highlights concerns over rising intermediate-term rates and inflation pressures impacting mortgage-backed securities.
The outlook remains cautious due to interest rate sensitivity and convexity risks in the mortgage market. While institutional buying by firms like Corient Private Wealth provides some support, the bearish technicals and macroeconomic headwinds suggest limited near-term upside. Key risks include further rate hikes and prepayment volatility in the MBS portfolio.
Vertex Pharmaceuticals (VRTX) trades at $510.08, up 0.88% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong 2025 results with $12B revenue and $4B net income, though recent quarterly earnings show inconsistent performance against expectations. Positive Phase 2b data for inaxaplin in kidney disease highlights pipeline progress beyond cystic fibrosis dominance.
Wall Street maintains strong bullish sentiment with 84% buy ratings and $573.50 consensus target, but risks include competitive pressures and reliance on CF franchise. The stock's premium valuation (P/E 29.31) requires continued execution on pipeline expansion to justify upside potential amid technical resistance near $515.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
